ARCHIVES

FDA approves a new cancer drug, Vidaza, and two sNDAs, without going to ODAC. A date with ODAC may signal a weak case for drug approval, recent approval data indicate.

This article is from The Cancer Letter archive.

Vol. 30 No. 22 | May 28, 2004

Download PDF Visit The Full Archive

Related Articles

Weicker Ready To Fight for Increased NCI, NIH Funding, Objects to Limits On Grants, Positions

March 14, 1986

Stand Up To Cancer Launches Immunology “Dream Team”

December 14, 2012

Advocates Call For Metrics And Action Plan In NCI’s Redesign of Cooperative Groups

July 8, 2011

NCI “Rescues” 31 Grants From Other Institutes, Funds Them at 41.6 Million; Scores Were 148-270

August 9, 1974

Trials Approved by NCI CTEP For The Month of February

February 24, 2012

José Baselga Named Physician-in-Chief Of Memorial Sloan-Kettering Hospital

September 21, 2012